Pseudoprogression and improvement of quality of life in a patient with advanced endometrial cancer treated with immunotherapy: a case report

Abstract

Until recently, treatment options for patients with recurrent or metastatic endometrial cancer (EC) were limited. First-line treatment is usually based on carboplatin and paclitaxel and there was no standard second- line therapy following platinum failure. However, the introduction of immunotherapy has expanded both first-line and later-line options for EC and made determination of mismatch repair status essential. We describe the case of a 56-year-old woman with deficient mismatch repair/microsatellite instability EC who did not respond to first-line treatment with carboplatin and paclitaxel but had a high response to subsequent immunotherapy with dostarlimab. There was initial pseudoprogression of one target lesion but marked improvement in quality of life.

This article is part of the New treatment options for advanced endometrial carcinoma Special Issue: https://www.drugsincontext.com/special_issues/new-treatment-options-for-advanced-endometrial-carcinoma